Reversing course, Lilly to seek fast approval for experimental Alzheimer's drug

Eli Lilly plans to seek accelerated Food and Drug Administration approval for its experimental Alzheimer's medicine donanemab, announcing Thursday plans to file an application with the agency later this year.